PV24 Speakers

Subject to change.

 

 

image

Eun Yeong Oh, MD, PhD

Assistant Regional Medical Director, Mid-Atlantic Permanente Medical Group

Dr. Eun Yeong Oh is the assistant medical director of Pathology and Laboratory Medicine, subspecialty chief of breast pathology, and a Physician Champion of Artificial Intelligence (AI) Center of Excellence at the Mid-Atlantic Permanente Medical Group (MAPMG).

 

Dr. Oh studied chemistry and mathematics at Emory University and received a combined MD-PhD degrees at University of South Carolina School of Medicine. She joined MAPMG in 2016 after completing anatomic and clinical pathology residency and breast pathology fellowship at Beth Israel Deaconess Medical Center-Harvard Medical School. Since joining MAPMG, she has standardized breast specimen handling and diagnostic workflows and implemented several image analysis platforms, including HALO Breast IHC AI, to analyze breast prognostic markers. She has also implemented three different digital pathology platforms to reduce cost, increase diagnostic efficiency, and expand intraprocedural pathology support across the region. 

 

Dr. Oh is board certified by American Board of Pathology and American Board of Artificial Intelligence (AI) in Medicine.

 

 

SESSIONS

[Indica Labs] Implementation of Breast IHC AI at Kaiser Permanente
   Sun, Nov 3
   04:00PM - 05:00PM ET
  Regency P

In this one-hour pre-conference workshop, Indica Labs is pleased to host Dr. Eun Yeong Oh, MD, PhD, Assistant Regional Medical Director, Subchief of Breast Pathology, and Physician AI Champion at Mid-Atlantic Permanente Medical Group (MAPMG), who will present on the validation and implementation of a laboratory developed test using Breast IHC AI in the HALO AP® platform. This workshop will cover how MAPMG/KPMAS selected HALO AP® and Breast IHC AI, and how they developed a business case for moving from a semi-quantitative workflow to a quantitative workflow for the analysis of ER, PR, HER2, and Ki67 in breast cancer. A timeline showcasing the selection of AI tools and their deployment as well as insights gained during deployment will be shared. Deidentified patient cases will be presented to illustrate the workflow and advantages of using AI analysis, as well as opportunities for further development of AI analysis. Finally, validation data acquired at MAPMG/KPMAS will be shared. As an introduction to the workshop, Steven Hashagen, CEO at Indica Labs, will provide a tour of Indica's broad suite of digital pathology products, demonstrating the use of the HALO platform from bench-to-bedside.

Chat bot